Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00089440
First received: August 5, 2004
Last updated: October 25, 2007
Last verified: July 2005

August 5, 2004
October 25, 2007
June 2004
Not Provided
  • Adverse effect measures
  • pharmacokinetic assessment
Same as current
Complete list of historical versions of study NCT00089440 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
Assessment of Interactions Between IV Methamphetamine and Aripiprazole

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.

Interventional
Phase 1
Primary Purpose: Treatment
Amphetamine-Related Disorders
Drug: Aripiprazole
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
17
March 2005
Not Provided

Inclusion Criteria:

  • Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.
  • Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.

Exclusion Criteria:

  • Please contact the site for more information.
Both
18 Years to 45 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00089440
NIDA-MDS-0002-1
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Thomas Newton, M.D. University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP